Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning

Authors: Ceccherini-Silberstein F, Cento V, Cuypers L, Di Maio VC, Libin P, Lunar MM, Nevens F, Nowé A, Poljak M, Schrooten Y, Theys K, Van Laethem K, Vandamme AM
Publication Year: 2017
Journal: Infection Genetics and Evolution
Link: https://www.sciencedirect.com/science/article/pii/S1567134817301582?via%3Dihub

Resistance-associated variants (RAVs) have been shown to influence treatment response to direct-acting antivirals (DAAs) and first generation NS3/4A protease inhibitors (PIs) in particular. Interpretation of hepatitis C virus (HCV) genotypic drug resistance remains a challenge, especially in patients who previously failed DAA therapy and need to be retreated with a second DAA based regimen. Bayesian […]
Read More

Zika virus genetic diversity and selective pressure: importance for diagnostics, vaccines and therapeutics

Authors: Abecasis A, Cuypers L, Libin P, Theys K, Vandamme AM
Publication Year: 2017
Journal: Tropical Medicine & International Health

During the last years, an increasing number of Zika virus (ZIKV) infections has been reported in Asia and America. Due to socio-environmental factors that remain to be established, this arbovirus has explosively spread to more than 60 countries worldwide. ZIKV infections can result into severe clinical manifestations, with little knowledge available to date about how […]
Read More

HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial

Authors: Crabbe R, Cuypers L, Kerremans L, Libin P, Snoeck J, Van Dooren S, Vandamme AM, Vuagniaux G
Publication Year: 2016
Journal: Infection Genetics and Evolution
Link: https://www.sciencedirect.com/science/article/pii/S156713481630274X?via%3Dihub

Major advances have revolutionized the HCV antiviral treatment field, with interferon-free combinations of direct-acting antivirals (DAAs) resulting into success rates of >90% for all HCV genotypes. Nevertheless, viral eradication at a global level stills remains challenging, stimulating the continued search for new affordable pan-genotypic drugs. To overcome selection of drug resistant variants, targeting host proteins […]
Read More

A near-full length genotypic assay for HCV1b

Authors: Camacho RJ, Cuypers L, Kerremans L, Nevens F, Snoeck J, Van Dooren S, Vandamme AM, Verbeeck J, Vrancken B, Vuagniaux G
Publication Year: 2014
Journal: Journal of Virological Methods
Link: http://www.ncbi.nlm.nih.gov/pubmed/25245140

A near-full genome genotypic assay for HCV1b was developed, which may prove useful to investigate antiviral drug resistance, given new combination therapies for HCV1 infection. The assay consists of three partially overlapping PCRs followed by Sanger population or Illumina next-generation sequencing.
Read More

Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning

Zika virus genetic diversity and selective pressure: importance for diagnostics, vaccines and therapeutics

HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial

A near-full length genotypic assay for HCV1b

About GHTM

Contacts

Funding